[{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Large Molecule","year":"2020","type":"Financing","leadProduct":"P014","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Kira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kira Pharmaceuticals \/ Quan Capital","highestDevelopmentStatusID":"3","companyTruncated":"Kira Pharmaceuticals \/ Quan Capital"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.

                          Product Name : P014

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          December 11, 2020

                          Lead Product(s) : P014

                          Therapeutic Area : Immunology

                          Highest Development Status : Discovery Platform

                          Sponsor : Quan Capital

                          Deal Size : $46.0 million

                          Deal Type : Financing

                          blank